CALL US
+91 9891296838/9811747774

KISQALI (ribociclib) tablets for oral use.
Initial U.S. Approval: 2017. Available In India.

KISQALI (ribociclib) tablets is a prescription medicine. KISQALI (ribociclib) tablets is used to treat postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. If you have questions, please email IPN Support Team or Call Indian Pharma Network on +91 9891296838 (Mr. Tarun) / 9811747774 (Mr. Neeraj) for price list or cost in India.

KISQALI (ribociclib) tablets is a prescription medicine. KISQALI (ribociclib) tablets is used to treat postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer

Source content : www.accessdata.fda.gov

KISQALI (ribociclib) tablets injection suppliers for India and other countries. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of KISQALI (ribociclib) tablets injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the KISQALI (ribociclib) tablets injection medicine cost price in India.

The order for KISQALI (ribociclib) tablets injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Ribociclib was approved by the U.S. Food and Drug Administration (FDA) in March 2017, and the European Medicines Agency (EMA) in August 2017, for use in combination with an aromatase inhibitor (such as letrozole) to treat HR-positive, HER2-negative advanced or metastatic breast cancers. In the clinical trial relevant for the drug's approval, ribociclib significantly improved progression-free survival (PFS), that is, the time span the cancer did not get worse. For patients receiving placebo plus letrozole, PFS was 16 months on average, while under ribociclib plus letrozole, PFS was 25 months as of the January 2017 analysis. The study is scheduled to run until September 2020.

KISQALI (ribociclib) tablets, for oral use.
Initial U.S. Approval: 2017.

Tablets: 200 mg
Please see the Full Prescribing Information, including Patient Information, for KISQALI.
KISQALI ® (ribociclib) tablets injection
You must agree before submitting.

News / Update for KISQALI (ribociclib) tablets .

For KISQALI (ribociclib) Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details

Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer For More Details

Kisqali Prolongs Overall Survival in Advanced Breast Cancer Patients with Internal Organ Metastases ReadMore

Steps to access KISQALI (ribociclib) tablets.

Step 1. You send a request for your medicine online:- Submit a request for a specific medicine, or a general request, and your Patient Support Manager will contact you within 24 hours. They will be there to support and guide you in anyway possible to help you get the medicine you need.

Step 2. We verify your prescription and medical details:- Since we help patients access medicines not available in their home country, our first step is to check that the medicine you need is not currently available in your home country. Next we will also verify that you have a prescription from a doctor in your home country for the medicine you need.

Step 3. We source your medicine:- Once we have verified your prescription and medical details, our expert sourcing team will work with our global network of suppliers to find you the best price. Once we have found you the lowest possible cost for your medicine, we will present you with a final offer for your approval.

Step 4. We deliver your medicine:- After you have accepted our offer, our experienced logistics team will arrange all the shipping and transportation of your medicine.

Documentation under Named-Patient import

Doctor’s Prescription –
We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.

Patient’s Medical history –
We would require all test reports and medical reports of the patient for last 3 months.

Patient’s Identity card –
We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

KISQALI (ribociclib) tablets exporter and suppliers in India

Can I get anti-cancer medicines even if I am not based in India?
Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. Indian Pharma Network, New Delhi can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of -
KISQALI (ribociclib) tablets in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
KISQALI (ribociclib) tablets in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
KISQALI (ribociclib) tablets in North America – Mexico.
KISQALI (ribociclib) tablets in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
KISQALI (ribociclib) tablets in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
KISQALI (ribociclib) tablets in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
KISQALI (ribociclib) tablets in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
KISQALI (ribociclib) tablets in Australia and New Zealand.

Room temperature shipping

For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.

Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised cold chain couriers. If you would like your order to be shipped by a specific courier, please inform us when you place the order. Our standard delivery time varies from 5 to 10 working days. The shipping cost depends on the medicine and the destination country. After making an enquiry, you will receive a detailed quote that includes the shipping costs.

IPN, New Delhi a trusted pharmaceutical exporter and wholesaler for Anti-Cancer Medicines in India.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur